Denis Poddubnyy

List of Publications by Year in Descending Order

211 papers	5,546 citations	39 h-index	71 g-index
276 ext. papers	7,571 ext. citations	4.3 avg, IF	6.28 L-index

#	Paper	IF	Citations
211	What amount of structural damage defines sacroiliitis: a CT study.. *RMD Open*, **2022**, 8,	5.9	1
210	Corticosteroids as risk factor for COVID-19-associated pulmonary aspergillosis in intensive care patients.. *Critical Care*, **2022**, 26, 30	10.8	5
209	Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy.. *Seminars in Arthritis and Rheumatism*, **2022**, 53, 151974	5.3	0
208	Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional study.. *Therapeutic Advances in Musculoskeletal Disease*, **2022**, 14, 1759720X221085951	3.8	1
207	Spondyloarthritiden im Kindes- und Erwachsenenalter. *Journal Fü Mineralstoffwechsel & Muskuloskelettale Erkrankungen*, **2022**, 29, 3-11	0.1	
206	Contrast-enhanced CT techniques and MRI perform equally well in arthritis imaging of the hand: a prospective diagnostic accuracy study.. *European Radiology*, **2022**, 1	8	0
205	Presence of spondyloarthritis associated to higher disease activity and HLA-B27 positivity in patients with early Crohn's disease: clinical and MRI results from a prospective inception cohort.. *Joint Bone Spine*, **2022**, 105367	2.9	0
204	Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?' by Braun and Landew.. *Annals of the Rheumatic Diseases*, **2022**,	2.4	1
203	How is early spondyloarthritis defined in the literature? Results from a systematic review. *Seminars in Arthritis and Rheumatism*, **2022**, 55, 152032	5.3	0
202	Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial. *BMJ Open*, **2021**, 11, e048647	3	2
201	Le sécukinumab améliore durablement les symptômes de spondyloarthrite axiale non-radiographique : résultats à 2 ans de l'étude PREVENT. *Revue Du Rhumatisme (Edition Francaise)*, **2021**, 88, A212-A213	0.1	
200	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X211057975	3.8	1
199	Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X211051471	3.8	0
198	Patient-Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey. *Arthritis Care and Research*, **2021**, 73, 1826-1833	4.7	2
197	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. *Journal of Rheumatology*, **2021**,	4.1	4
196	Diagnosing axial spondyloarthritis: estimation of the disease probability in patients with a priori different likelihoods of the diagnosis. *Rheumatology*, **2021**, 60, 5098-5104	3.9	1
195	Differential diagnostic value of rheumatic symptoms in patients with Whipple's disease. *Scientific Reports*, **2021**, 11, 5980	4.9	3

194	Impact of age, sex, and joint form on degenerative lesions of the sacroiliac joints on CT in the normal population. *Scientific Reports*, **2021**, 11, 5903	4.9	4
193	Joint anatomy in axial spondyloarthritis: strong associations between sacroiliac joint form variation and symptomatic disease. *Rheumatology*, **2021**,	3.9	7
192	Diagnostic delay in axial spondyloarthritis - a past or current problem?. *Current Opinion in Rheumatology*, **2021**, 33, 307-312	5.3	3
191	Identifying Parameters Associated with Delayed Diagnosis in Axial Spondyloarthritis: Data from the European Map of Axial Spondyloarthritis. *Rheumatology*, **2021**,	3.9	4
190	The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. *British Journal of Dermatology*, **2021**, 185, 935-944	4	10
189	Deep learning for detection of radiographic sacroiliitis: achieving expert-level performance. *Arthritis Research and Therapy*, **2021**, 23, 106	5.7	9
188	POS0923 INFLUENCE OF BASELINE DEMOGRAPHICS ON IMPROVEMENTS IN DISEASE ACTIVITY MEASURES IN PATIENTS WITH ANKYLOSING SPONDYLITIS RECEIVING UPADACITINIB: A POST HOC SUBGROUP ANALYSIS OF SELECT-AXIS 1. *Annals of the Rheumatic Diseases*, **2021**, 80, 722.2-723	2.4	
187	POS1002 BASELINE CALPROTECTIN AND VISFATIN LEVELS PREDICT RADIOGRAPHIC SPINAL PROGRESSION AFTER 2 YEARS IN ANKYLOSING SPONDYLITIS PATIENTS ON TNF INHIBITOR THERAPY. *Annals of the Rheumatic Diseases*, **2021**, 80, 769.2-770	2.4	
186	CT-like images of the sacroiliac joint generated from MRI using susceptibility-weighted imaging (SWI) in patients with axial spondyloarthritis. *RMD Open*, **2021**, 7,	5.9	8
185	OP0139 A TIME-SHIFTED EFFECT OF TUMOR NECROSIS FACTOR INHIBITORS ON RADIOGRAPHIC SPINAL PROGRESSION IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: LONG-TERM RESULTS FROM THE GERMAN SPONDYLOARTHRITIS INCEPTION COHORT. *Annals of the Rheumatic Diseases*,	2.4	
184	OP0031 SHARED AND DISTINCT GUT MICROBIOME SIGNATURES IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND ITS RELATED IMMUNE-MEDIATED DISEASES. *Annals of the Rheumatic Diseases*, **2021**, 80, 17.1-17	2.4	
183	POS1007 OPTIMIZING A REFERRAL STRATEGY FOR PATIENTS WITH A HIGH PROBABILITY OF AXIAL SPONDYLOARTHRITIS: THE ROLE OF AGE AND SYMPTOM DURATION. *Annals of the Rheumatic Diseases*, **2021**, 80, 771.3-772	2.4	
182	Twenty years of clinical trials in axial spondyloarthritis: what can we learn for the future?. *Current Opinion in Rheumatology*, **2021**, 33, 363-369	5.3	1
181	Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y). *Annals of the Rheumatic Diseases*, **2021**,	2.4	5
180	OP0048 DIAGNOSING AXIAL SPONDYLOARTHRITIS: ESTIMATION OF THE DISEASE PROBABILITY IN PATIENTS WITH A PRIORI DIFFERENT LIKELIHOODS OF THE DIAGNOSIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 25-26	2.4	
179	POS0244 PATIENT JOURNEY WITH AXIAL SPONDYLOARTHRITIS: CRITICAL ISSUES FROM THE PATIENT PERSPECTIVE. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). *Annals of the Rheumatic Diseases*, **2021**, 80, 343.2-344	2.4	
178	POS0453 VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) WITH A QUICK QUANTITATIVE C-REACTIVE PROTEIN ASSAY (SDAI-Q) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A NATIONAL, MULTICENTER STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 456.2-457	2.4	1
177	POS0969 UNVEILING AXIAL INVOLVEMENT IN PSORIATIC ARTHRITIS: AN ANCILLARY ANALYSIS OF THE ASAS-perSpA STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 750-751	2.4	1

176	Choose wisely: imaging for diagnosis of axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2021**,	2.4	8
175	POS0226 BIMEKIZUMAB LONG-TERM SAFETY AND EFFICACY IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 3-YEAR RESULTS FROM A PHASE 2B STUDY. *Annals of the Rheumatic Diseases*, **2021**, 80, 332-333	2.4	0
174	POS0065-PARE HEALTH IMPACT OF OVERWEIGHT AND OBESITY IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). *Annals of the Rheumatic Diseases*, **2021**, 80, 239.2-239	2.4	
173	OP0256 CHOOSE WISELY: IMAGING FOR DIAGNOSIS OF AXIAL SPONDYLOARTHRITIS. *Annals of the Rheumatic Diseases*, **2021**, 80, 156.2-157	2.4	1
172	POS0990 FACTORS ASSOCIATED WITH ENGAGING IN PHYSICAL ACTIVITY IN AXIAL SPONDYLOARTHRITIS. RESULTS FROM THE EUROPEAN MAP OF AXIAL SPONDYLOARTHRITIS (EMAS). *Annals of the Rheumatic Diseases*, **2021**, 80, 763.1-763	2.4	
171	Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study. *Arthritis and Rheumatology*, **2021**, 73, 110-120	9.5	44
170	Assessment of radiographic sacroiliitis in anteroposterior lumbar vs conventional pelvic radiographs in axial spondyloarthritis. *Rheumatology*, **2021**, 60, 269-276	3.9	1
169	Peripheral blood mononuclear cells are hypomethylated in active rheumatoid arthritis and methylation correlates with disease activity. *Rheumatology*, **2021**, 60, 1984-1995	3.9	8
168	Precision medicine in rheumatology: are we getting closer?. *Lancet, The*, **2021**, 397, 258-259	40	4
167	Gender differences in patient journey to diagnosis and disease outcomes: results from the European Map of Axial Spondyloarthritis (EMAS). *Clinical Rheumatology*, **2021**, 40, 2753-2761	3.9	7
166	Asymptomatic secondary hyperparathyroidism can mimic sacroiliitis on computed tomography. *Scientific Reports*, **2021**, 11, 4323	4.9	0
165	Radiographic sacroiliitis progression in axial spondyloarthritis: central reading of 5 year follow-up data from the Assessment of SpondyloArthritis international Society cohort. *Rheumatology*, **2021**, 60, 2478-2480	3.9	1
164	Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility. *Rheumatology*, **2021**, 60, 4778-4789	3.9	13
163	Axial involvement in psoriatic arthritis: An update for rheumatologists. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 880-887	5.3	8
162	Detection of radiographic sacroiliitis with an artificial neural network in patients with suspicion of axial spondyloarthritis. *Rheumatology*, **2021**, 60, 5868-5869	3.9	0
161	The ASAS-OMERACT core domain set for axial spondyloarthritis. *Seminars in Arthritis and Rheumatism*, **2021**,	5.3	6
160	Unveiling axial involvement in psoriatic arthritis: An ancillary analysis of the ASAS-perSpA study. *Seminars in Arthritis and Rheumatism*, **2021**, 51, 766-774	5.3	2
159	Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. *Arthritis Research and Therapy*, **2021**, 23, 231	5.7	3

158	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. *Lancet Rheumatology, The*, **2021**, 3, e715-e723	14.2	14
157	Sustained clinical response and safety of etanercept in patients with early axial spondyloarthritis: 10-year results of the ESTHER trial. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X20987700	3.8	2
156	Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria. *Annals of the Rheumatic Diseases*, **2020**, 79, 935-942	2.4	4
155	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Annals of the Rheumatic Diseases*, **2020**, 79, 700-712	2.4	238
154	Axial Psoriatic Arthritis: A Distinct Clinical Entity in Search of a Definition. *Rheumatic Disease Clinics of North America*, **2020**, 46, 327-341	2.4	6
153	Fibrinogen, factor XIII and α2-antiplasmin genotypes are associated with inflammatory activity and anti-citrullinated protein antibodies. *Thrombosis Research*, **2020**, 191, 90-96	8.2	2
152	Comment on: 'Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis' by Kuwabara. *Annals of the Rheumatic Diseases*, **2020**,	2.4	5
151	Comparison of the Effects of Secukinumab and Adalimumab Biosimilar on Radiographic Progression in Patients with Ankylosing Spondylitis: Design of a Randomized, Phase IIIb Study (SURPASS). *Clinical Drug Investigation*, **2020**, 40, 269-278	3.2	16
150	Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. *Annals of the Rheumatic Diseases*, **2020**, 79, 595-604	2.4	46
149	OP0054 EFFICACY OF GUSELKUMAB, A MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO THE P19-SUBUNIT OF IL-23, ON ENDPOINTS RELATED TO AXIAL INVOLVEMENT IN PATIENTS WITH ACTIVE PSA WITH IMAGING-CONFIRMED SACROILIITIS: WEEK-24 RESULTS FROM TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES. *Annals of the Rheumatic Diseases* , 2020, 79, 36-37	2.4	9
148	GRAPPA 2019 Project Report. *Journal of Rheumatology*, **2020**, 96, 53-57	4.1	6
147	OP0106 SECUKINUMAB 150 MG SIGNIFICANTLY IMPROVED SIGNS AND SYMPTOMS OF NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: 52-WEEK RESULTS FROM THE PHASE III PREVENT STUDY. *Annals of the Rheumatic Diseases*, **2020**, 79, 69-70	2.4	2
146	Clinical and imaging characteristics of osteitis condensans ilii as compared with axial spondyloarthritis. *Rheumatology*, **2020**, 59, 3798-3806	3.9	21
145	Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. *Lancet, The*, **2020**, 395, 53-64	40	74
144	Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate. *BMJ Open*, **2020**, 10, e039059	3	2
143	Comparison of an online self-referral tool with a physician-based referral strategy for early recognition of patients with a high probability of axial spa. *Seminars in Arthritis and Rheumatism*, **2020**, 50, 1015-1021	5.3	14
142	Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. *Rheumatology*, **2020**, 59, iv6-iv17	3.9	23
141	Treatment of Axial Spondyloarthritis: What Does the Future Hold?. *Current Rheumatology Reports*, **2020**, 22, 47	4.9	11

140	Ixekizumab dans la spondyloarthrite axiale non-radiographique : résultats d'un essai de phase 3. *Revue Du Rhumatisme (Edition Francaise)*, **2020**, 87, A165-A166	0.1	
139	Secukinumab Provides Sustained Reduction in Fatigue in Patients with Ankylosing Spondylitis: Long-term Results of Two Phase III Randomized Controlled Trials. *Arthritis Care and Research*, **2020**,	4.7	3
138	Uveitis in spondyloarthritis. *Therapeutic Advances in Musculoskeletal Disease*, **2020**, 12, 1759720X20951738	3.8	14
137	The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. *Arthritis Research and Therapy*, **2020**, 22, 210	5.7	9
136	The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study. *Therapeutic Advances in Musculoskeletal Disease*, **2020**, 12, 1759720X20972610	3.8	4
135	Skin manifestations in spondyloarthritis. *Therapeutic Advances in Musculoskeletal Disease*, **2020**, 12, 1759720X20975915	3.8	3
134	Performance of the Ankylosing Spondylitis Disease Activity Score based on a quick quantitative C-reactive protein assay in patients with axial spondyloarthritis. *Joint Bone Spine*, **2020**, 87, 69-73	2.9	4
133	IgA antibodies against CD74 are associated with structural damage in the axial skeleton in patients with axial spondyloarthritis. *Clinical and Experimental Rheumatology*, **2020**, 38, 1127-1131	2.2	3
132	MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group. *Annals of the Rheumatic Diseases*, **2019**, 78, 1550-1558	2.4	81
131	Emerging drugs for the treatment of noninfectious uveitis. *Expert Opinion on Emerging Drugs*, **2019**, 24, 173-190	3.7	5
130	The IL-23-IL-17 pathway as a therapeutic target in axial spondyloarthritis. *Nature Reviews Rheumatology*, **2019**, 15, 747-757	8.1	45
129	Detection of Sacroiliitis by Short-tau Inversion Recovery and T2-weighted Turbo Spin Echo Sequences: Results from the SIMACT Study. *Journal of Rheumatology*, **2019**, 46, 376-383	4.1	10
128	Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. *Arthritis Research and Therapy*, **2019**, 21, 142	5.7	17
127	Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis. *Arthritis Research and Therapy*, **2019**, 21, 126	5.7	1
126	Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. *Rheumatology*, **2019**, 58, 1634-1638	3.9	52
125	Pharmacologic Nonbiologic Treatment of Axial Spondyloarthritis **2019**, 217-226		
124	Added value of biomarkers compared with clinical parameters for the prediction of radiographic spinal progression in axial spondyloarthritis. *Rheumatology*, **2019**, 58, 1556-1564	3.9	11
123	The European Map of Axial Spondyloarthritis: Capturing the Patient Perspective-an Analysis of 2846 Patients Across 13 Countries. *Current Rheumatology Reports*, **2019**, 21, 19	4.9	29

122	IL-17 inhibition in axial spondyloarthritis: current and future perspectives. *Expert Opinion on Biological Therapy*, **2019**, 19, 631-641	5.4	12
121	HLA-C*07 in axial spondyloarthritis: data from the German Spondyloarthritis Inception Cohort and the Spondyloarthritis Caught Early cohort. *Genes and Immunity*, **2019**, 20, 671-677	4.4	
120	Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno. *Annals of the Rheumatic Diseases*, **2019**, 78, e55	2.4	
119	Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts. *Annals of the Rheumatic Diseases*, **2019**, 78, 1545-1549	2.4	27
118	Current Unmet Needs in Spondyloarthritis. *Current Rheumatology Reports*, **2019**, 21, 43	4.9	7
117	Reality of care for musculoskeletal diseases at the population level : Results of the PROCLAIR collaborative project. *Zeitschrift Fur Rheumatologie*, **2019**, 78, 73-79	1.9	2
116	Balancing benefits and risks in the era of biologics. *Therapeutic Advances in Musculoskeletal Disease*, **2019**, 11, 1759720X19883973	3.8	2
115	Should we combine biologics with methotrexate in axial spondyloarthritis?. *Autoimmunity Reviews*, **2019**, 18, 102402	13.6	1
114	Response to: 'Irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Wallman. *Annals of the Rheumatic Diseases*, **2019**,	2.4	1
113	Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. *RMD Open*, **2019**, 5, e001005	5.9	40
112	Ist eine Hemmung der r□ntgenologischen Progression bei axialer Spondyloarthritis m□glich?. *Aktuelle Rheumatologie*, **2019**, 44, 352-359	0.1	
111	Susceptibility-weighted MR imaging to improve the specificity of erosion detection: a prospective feasibility study in hand arthritis. *Skeletal Radiology*, **2019**, 48, 721-728	2.7	6
110	Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. *Rheumatology*, **2019**, 58, 859-868	3.9	72
109	Progression of Structural Damage in the Sacroiliac Joints in Patients With Early Axial Spondyloarthritis During Long-Term Anti-Tumor Necrosis Factor Treatment: Six-Year Results of Continuous Treatment With Etanercept. *Arthritis and Rheumatology*, **2019**, 71, 722-728	9.5	13
108	Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors. *Arthritis and Rheumatology*, **2019**, 71, 599-611	9.5	96
107	Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis. *Annals of the Rheumatic Diseases*, **2019**, 78, 31-35	2.4	6
106	Emerging drugs for the treatment of axial spondyloarthritis. *Expert Opinion on Emerging Drugs*, **2018**, 23, 83-96	3.7	9
105	Restless legs syndrome is a relevant comorbidity in patients with inflammatory bowel disease. *International Journal of Colorectal Disease*, **2018**, 33, 955-962	3	9

104	Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. *Rheumatology*, **2018**, 57, 703-711	3.9	23
103	Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity. *Arthritis Research and Therapy*, **2018**, 20, 44	5.7	10
102	Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. *Annals of the Rheumatic Diseases*, **2018**, 77, 1017-1024	2.4	25
101	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. *Annals of the Rheumatic Diseases*, **2018**, 77, 3-17	2.4	320
100	What is the best treatment target in axial spondyloarthritis: tumour necrosis factor ␣interleukin 17, or both?. *Rheumatology*, **2018**, 57, 1145-1150	3.9	15
99	Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. *Annals of the Rheumatic Diseases*, **2018**, 77, 1585-1589	2.4	35
98	Emerging treatment options for spondyloarthritis. *Best Practice and Research in Clinical Rheumatology*, **2018**, 32, 472-484	5.3	10
97	Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care. *RMD Open*, **2018**, 4, e000825	5.9	24
96	LB0001 Dual neutralisation of il-17a and il-17f with bimekizumab in patients with active ankylosing spondylitis (AS): 12-week results from a phase 2b, randomised, double-blind, placebo-controlled, dose-ranging study **2018**,		3
95	Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. *Lancet, The*, **2018**, 392, 2441-2451	40	161
94	An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus. *Arthritis Research and Therapy*, **2018**, 20, 191	5.7	9
93	Radiographic progression in non-radiographic axial spondyloarthritis. *Expert Review of Clinical Immunology*, **2018**, 14, 525-533	5.1	30
92	Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. *Therapeutic Advances in Musculoskeletal Disease*, **2018**, 10, 129-139	3.8	39
91	Axial spondyloarthritis. *Lancet, The*, **2017**, 390, 73-84	40	451
90	Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. *Annals of the Rheumatic Diseases*, **2017**, 76, 1502-1508	2.4	88
89	Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial. *BMJ Open*, **2017**, 7, e014591	3	9
88	Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?. *Immunotherapy*, **2017**, 9, 899-911	3.8	3
87	Chronic meningococcaemia-a medical oxymoron. *Rheumatology*, **2017**, 56, 1819-1821	3.9	

86	Tumor necrosis factor-α (TNF) inhibitors in the treatment of nonradiographic axial spondyloarthritis: current evidence and place in therapy. *Therapeutic Advances in Musculoskeletal Disease*, **2017**, 9, 197-210	3.8	8
85	Mechanism of New Bone Formation in Axial Spondyloarthritis. *Current Rheumatology Reports*, **2017**, 19, 55	4.9	30
84	Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial. *Arthritis Research and Therapy*, **2017**, 19, 140	5.7	31
83	Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Arthritis Research and Therapy*, **2017**, 19, 240	5.7	23
82	Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). *Annals of the Rheumatic Diseases*, **2016**, 75, 1438-43	2.4	123
81	THU0407 Baseline Results from Proof A 5-Year Observational Study of Long-Term Disease Outcome in Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 335.3-336	2.4	
80	Physical Function and Spinal Mobility Remain Stable Despite Radiographic Spinal Progression in Patients with Ankylosing Spondylitis Treated with TNF-inhibitors for Up to 10 Years. *Journal of Rheumatology*, **2016**, 43, 2142-2148	4.1	29
79	SAT0422 Long-Term anti-TNF Treatment Is Associated with Reduction of Progression of Radiographic Changes in The Sacroiliac Joints in Patients with Non-Radiographic Axial SpA: Six-Year Results of The Esther Trial. *Annals of the Rheumatic Diseases*, **2016**, 75, 823.2-824	2.4	
78	Golimumab for treatment of axial spondyloarthritis. *Immunotherapy*, **2016**, 8, 107-15	3.8	1
77	Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. *Annals of the Rheumatic Diseases*, **2016**, 75, 1958-1963	2.4	259
76	Etanercept for the treatment of non-radiographic axial spondyloarthritis. *Expert Review of Clinical Immunology*, **2016**, 12, 493-500	5.1	2
75	Inflammatory and fatty lesions in the spine and sacroiliac joints on whole-body MRI in early axial spondyloarthritis--3-Year data of the ESTHER trial. *Seminars in Arthritis and Rheumatism*, **2016**, 45, 404-10	5.3	27
74	FRI0397 The Diagnostic Value of The Symptom of Inflammatory Back Pain in Axial Spondyloarthritis in The Rheumatology Setting. *Annals of the Rheumatic Diseases*, **2016**, 75, 578.3-579	2.4	
73	THU0379 Clinical Disease Activity Measures Are Associated with Radiographic Spinal Progression in Early Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*, **2016**, 75, 324.2-325	2.4	
72	Brief Report: Course of Active Inflammatory and Fatty Lesions in Patients With Early Axial Spondyloarthritis Treated With Infliximab Plus Naproxen as Compared to Naproxen Alone: Results From the Infliximab As First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial. *Arthritis and Rheumatology*, **2016**, 68, 1899-903	9.5	11
71	Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and	9.5	32
70	High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. *Annals of the Rheumatic Diseases*, **2016**, 75, 2114-2118	2.4	71
69	OP0080 Higher Serum Level of Leptin Might Be Responsible for Less Structural Damage in The Spine in Female Patients with Ankylosing Spondylitis. *Annals of the Rheumatic Diseases*, **2016**, 75, 84.3-85	2.4	

68	New evidence on the management of spondyloarthritis. *Nature Reviews Rheumatology*, **2016**, 12, 282-958.1		77
67	Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2015**, 74, 1483-7	2.4	71
66	Serum adipokine levels in patients with ankylosing spondylitis and their relationship to clinical parameters and radiographic spinal progression. *Arthritis and Rheumatology*, **2015**, 67, 678-85	9.5	53
65	Blocking Interleukin-12 and Interleukin-23 in the Treatment of Axial Spondyloarthritis. *Current Treatment Options in Rheumatology*, **2015**, 1, 231-238	1.3	
64	Old and new treatment targets in axial spondyloarthritis. *RMD Open*, **2015**, 1, e000054	5.9	10
63	OP0145 Continuous Versus on Demand Treatment of Ankylosing Spondylitis with Diclofenac Over 2 Years Does not Prevent Radiographic Progression of the Spine Results from a Randomized Prospective Multi-Center Trial (Enradas). *Annals of the Rheumatic Diseases*, **2015**, 74, 123.2-123	2.4	3
62	THU0194 Serum Biomarkers Associated with Disease Activity and Response to Ustekinumab in Patients with Ankylosing Spondylitis in the Topas Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 265.1-265	2.4	
61	THU0200 Sustained and Similar Clinical Response to Etanercept After 6 Years of Treatment in Patients with Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis: Long-term Results of the Esther Trial. *Annals of the Rheumatic Diseases*, **2015**, 74, 267.2-268	2.4	
60	OP0172 No Differences in the Rate of New Fatty Lesions Following Resolution of Inflammation on MRI Between Infliximab Added to Naproxen and Naproxen Alone in Early Axial Spondyloarthritis: Results from the Part I of the Infast Study. *Annals of the Rheumatic Diseases*, **2015**, 74, 135.1-135	2.4	
59	Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort. *Arthritis and Rheumatology*, **2015**, 67, 2369-75	9.5	22
58	SAT0240 New Inflammatory Lesions in Axial Spondyloarthritis are More Likely to Occur in the Areas Already Affected by Inflammation in the Past. *Annals of the Rheumatic Diseases*, **2015**, 74, 745.2-745	2.4	
57	Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial. *Rheumatology*, **2015**, 54, 257-61	3.9	17
56	Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven et al. *Annals of the Rheumatic Diseases*, **2015**, 74, e69	2.4	2
55	THU0199 Functional Status Remains Stable Despite Continuous Radiographic Spinal Progression Over Ten Years in Patients with Ankylosing Spondylitis Receiving Anti-TNF Therapy. *Annals of the Rheumatic Diseases*, **2015**, 74, 267.1-267	2.4	
54	Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 2137-43	2.4	48
53	Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS). *Annals of the Rheumatic Diseases*, **2014**, 73, 817-23	2.4	195
52	Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. *Journal of Rheumatology* , **2014**, 41, 2034-40	4.1	23
51	AB0664 Efficacy and Safety of Methylprednisolone Administered Intravenously for the Treatment of Patients with Active Ankylosing Spondylitis: Results of A 12-Week, Prospective, Open-Label Study (METALL). *Annals of the Rheumatic Diseases*, **2014**, 73, 1024.3-1025	2.4	

50	FRI0114 Reaching A Status of Low Disease Activity Spontaneously over Two Year Follow-Up in Active Patients with Non-Radiographic Axial Spondyloarthritis in Comparison to Ankylosing Spondylitis not Treated with TNF Blockers. *Annals of the Rheumatic Diseases*, **2014**, 73, 422.3-423	2.4	1
49	THU0071 Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the GESPIC Cohort. *Annals of the Rheumatic Diseases*, **2014**, 73, 201.1-201	2.4	2
48	FRI0113 Persistently High Disease Activity According to the ASDAS is Associated with Accelerated Radiographic Spinal Progression in Patients with Axial Spondyloarthritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 422.2-422	2.4	
47	SAT0371 Ustekinumab Treatment in Ankylosing Spondylits (AS) Patients Does not Modulate Effector CD4+ T Cell Frequencies Including TH17 Cells. *Annals of the Rheumatic Diseases*, **2014**, 73, 727.3-728	2.4	
46	Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2014**, 73, 1746-8	2.4	61
45	OP0155 Ustekinumab Effectively Reduces Active Inflammation as Detected by Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of A 28-Week, Prospective, Open-Label, Proof-Of-Concept Study (TOPAS). *Annals of the Rheumatic Diseases*, **2014**, 73, 120.1-120	2.4	
44	Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. *Best Practice and Research in Clinical Rheumatology*, **2014**, 28, 807-18	5.3	14
43	Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical, epidemiological and therapeutic assessment. *Current Opinion in Rheumatology*, **2014**, 26, 377-83	5.3	46
42	FRI0169 Elevated LBP Levels and in Vivo Activation of Monocytes as Potential Indicators of Bacterial Translocation in Axial Spondyloarthritis: Table 1.. *Annals of the Rheumatic Diseases*, **2014**, 73, 443.1-443	2.4	
41	Cigarette smoking has a dose-dependent impact on progression of structural damage in the spine in patients with axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). *Annals of the Rheumatic Diseases*, **2013**, 72, 1430-2	2.4	56
40	Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update. *Expert Opinion on Biological Therapy*, **2013**, 13, 1599-611	5.4	5
39	Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. *Annals of the Rheumatic Diseases*, **2013**, 72, 823-5	2.4	79
38	Magnetic resonance imaging compared to conventional radiographs for detection of chronic structural changes in sacroiliac joints in axial spondyloarthritis. *Journal of Rheumatology*, **2013**, 40, 1557-65	4.1	39
37	FRI0423 Effective prevention of new inflammatory bony lesions on magnetic resonance imaging in patients with early axial spondyloarthritis during treatment with etanercept over 2 years - data of the esther trial. *Annals of the Rheumatic Diseases*, **2013**, 72, A517.2-A518	2.4	
36	Diagnostik und Klassifikation der Spondyloarthritiden 2012. *Aktuelle Rheumatologie*, **2013**, 38, 86-91	0.1	
35	Axial spondyloarthritis: is there a treatment of choice?. *Therapeutic Advances in Musculoskeletal Disease*, **2013**, 5, 45-54	3.8	30
34	THU0273 Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after one year of treatment with etanercept - results of the esther trial. *Annals of the Rheumatic Diseases*, **2013**, 71, 247.2-247	2.4	1
33	THU0358 Constant Clinical Response in Patients with Early Axial Spondyloarthritis after Continuous Treatment with Etanercept - 4 Year Data of the Esther Trial. *Annals of the Rheumatic Diseases*, **2013**, 72, A286.1-A286	2.4	

32	FRI0282 Insights into progression of structural damage of sacroiliac joints in patients with axial spondyloarthritis: Introduction of new scoring system for radiographic sacroiliitis. *Annals of the Rheumatic Diseases*, **2013**, 71, 409.2-409	2.4	
31	OP0097 Cigarette smoking predicts radiographic progression in the spine in patients with axial spondyloarthritis in a dose-dependent manner. *Annals of the Rheumatic Diseases*, **2013**, 71, 85.3-86	2.4	1
30	SAT0255 Predictive and protective role of adipokines in radiographic spinal progression in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2013**, 71, 558.1-558	2.4	
29	SAT0265 Ratio of non-radiographic and radiographic axial spondyloarthritis in patients referred because of back pain is dependent on symptom duration. *Annals of the Rheumatic Diseases*, **2013**, 71, 561.2-561	2.4	
28	OP0247 Reduction of radiographic spinal progression in patients with ankylosing spondylitis treated with non-steroidal anti-inflammatory drugs is most evident in the presence of syndesmophytes and active systemic inflammation. *Annals of the Rheumatic Diseases*, **2013**, 71, 139.1-139	2.4	
27	SAT0245 Elevated serum levels of sclerostin and periostin protect against syndesmophyte formation in patients with ankylosing spondylitis and high activity of systemic inflammation. *Annals of the Rheumatic Diseases*, **2013**, 71, 554.3-554	2.4	1
26	OP0091 Prediction of radiographic spinal progression using biomarkers in patients with ankylosing spondylitis who are at high risk for progression. *Annals of the Rheumatic Diseases*, **2013**, 71, 83.3-84	2.4	
25	THU0263 Development of chronic inflammatory changes on whole body magnetic resonance imaging in patients with early axial spondyloarthritis after two years of continuous treatment with etanercept 2 year data of the esther trial. *Annals of the Rheumatic Diseases*, **2013**, 71, 243.3-244	2.4	
24	NSAIDs for spondyloarthrits including ankylosing spondylitis **2013**, 46-58		
23	Wenn die Wirbelsule versteift. *Der Hausarzt*, **2013**, 50, 53-56		
22	Decreased heart rate variability in patients with psoriatic arthritis. *Clinical Rheumatology*, **2012**, 31, 1377-81	39	7
21	Early spondyloarthritis. *Rheumatic Disease Clinics of North America*, **2012**, 38, 387-403	2.4	38
20	Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. *Annals of the Rheumatic Diseases*, **2012**, 71, 1212-5	2.4	70
19	Therapeutic controversies in spondyloarthritis: nonsteroidal anti-inflammatory drugs. *Rheumatic Disease Clinics of North America*, **2012**, 38, 601-11	2.4	14
18	High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. *Annals of the Rheumatic Diseases*, **2012**, 71, 572-4	2.4	162
17	Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. *Annals of the Rheumatic Diseases*, **2012**, 71, 1616-22	2.4	223
16	Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. *Arthritis and Rheumatism*, **2012**, 64, 1388-98		287
15	Radiographic progression in ankylosing spondylitis/axial spondyloarthritis: how fast and how clinically meaningful?. *Current Opinion in Rheumatology*, **2012**, 24, 363-9	5.3	39

14	The frequency of non-radiographic axial spondyloarthritis in relation to symptom duration in patients referred because of chronic back pain: results from the Berlin early spondyloarthritis clinic. *Annals of the Rheumatic Diseases*, **2012**, 71, 1998-2001	2.4	43
13	Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. *Expert Opinion on Drug Safety*, **2011**, 10, 655-73	4.1	22
12	Improving diagnosis of ankylosing spondylitis and spondyloarthritis in general. *International Journal of Clinical Rheumatology*, **2011**, 6, 655-667	1.5	
11	New treatment targets in ankylosing spondylitis and other spondyloarthritides. *Current Opinion in Rheumatology*, **2011**, 23, 346-51	5.3	10
10	Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. *Journal of Rheumatology*, **2011**, 38, 2452-60	4.1	94
9	Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2011**, 70, 1369-74	2.4	209
8	Relation of HLA-B27, tumor necrosis factor-□promoter gene polymorphisms, and T cell cytokine production in ankylosing spondylitis -- a comprehensive genotype-phenotype analysis from an observational cohort. *Journal of Rheumatology*, **2011**, 38, 2436-41	4.1	14
7	Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. *Annals of the Rheumatic Diseases*, **2011**, 70, 1257-63	2.4	85
6	Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. *Annals of the Rheumatic Diseases*, **2010**, 69, 1338-41	2.4	50
5	Investigation of involved tissue in axial spondyloarthritis--what have we learnt from immunohistochemical studies?. *Best Practice and Research in Clinical Rheumatology*, **2010**, 24, 715-9	5.3	6
4	Adalimumab for the treatment of psoriatic arthritis. *Expert Review of Clinical Immunology*, **2009**, 5, 671-85	3.1	2
3	A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. *Clinical and Experimental Rheumatology*, **2009**, 27, S148-51	2.2	2
2	The safety of celecoxib in ankylosing spondylitis treatment. *Expert Opinion on Drug Safety*, **2008**, 7, 401-9	4.1	6
1	Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. *Arthritis and Rheumatism*, **2008**, 58, 929-38		80